APR ED022
Alternative Names: APR-ED022Latest Information Update: 08 Jul 2022
At a glance
- Originator APR Applied Pharma Research
- Class Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Eye disorders
Most Recent Events
- 06 Jul 2022 Preclinical trials in Eye disorders in Switzerland (unspecified route) as of July 2022 (APR Applied Pharma Research pipeline, July 2022)
- 05 Jul 2022 APR ED022 is available for licensing as of 05 Jul 2022. https://www.apr.ch/applied-pharma-research/healthcare-partners/
- 05 Jul 2022 APR Applied Pharma Research has patent protection for TEHCLO applied nanoscience technology as of July 2022 (APR Applied Pharma Research pipeline, July 2022) .